TL;DR
This study reveals that SARS-CoV-2 infection disrupts tryptophan metabolism, leading to increased levels of kynurenine and its metabolites. This metabolic shift activates the Aryl Hydrocarbon Receptor (AHR) and Tissue Factor (TF) pathway in blood vessel cells, contributing to the prothrombotic state seen in COVID-19. Targeting this Kynurenine-AHR-TF axis shows promise as a new therapeutic strategy for COVID-19-associated coagulopathy.
What Problem Does This Paper Address?
COVID-19 is known to cause a prothrombotic state, leading to dangerous blood clots and organ failure. While this coagulopathy is a major concern, the underlying molecular mechanisms, particularly the role of specific metabolites, remain unclear. This paper investigates how SARS-CoV-2 infection alters tryptophan metabolism and whether these changes contribute to the observed prothrombotic milieu, specifically by examining the Kynurenine-AHR-TF axis.
Methods
The researchers employed a multi-pronged approach:
- Animal Models: They used K18-hACE2 transgenic mice, which are susceptible to SARS-CoV-2 infection, to study the effects of the virus on tryptophan metabolism and the AHR-TF axis in vivo.
- Immunohistochemistry (IHC) and Immunofluorescence (IF): These techniques were used to visualize and quantify the expression of key enzymes (IDO-1, KMO, KYNU, TDO2) and proteins (AHR, TF) in tissue samples from infected mice and human autopsies.
- RT-PCR: This method was used to measure the mRNA expression levels of genes involved in tryptophan metabolism and the AHR-TF axis.
- LC/MS-based Metabolomics: This quantitative technique was used to measure the concentrations of various tryptophan metabolites in serum samples from both mice and human patients.
- Cell-based Assays: Human endothelial cells (HUVECs) were used to assess AHR activity, TF activity, and IDO-1 activity in response to sera from COVID-19 patients and to test the effects of pharmacological inhibitors.
- Pharmacological Manipulation: Inhibitors of AHR and IDO-1 were used to probe the functional role of this axis in TF activation.
Datasets
- Mouse Tissues: Liver, kidney, and lung tissues from K18-hACE2 mice infected with SARS-CoV-2 at various time points (2, 4, and 7 days post-infection) and mock-infected controls.
- Human Sera: Serum samples from 20 COVID-19 patients and 31 healthy controls.
- Human Autopsy Samples: Kidney autopsy samples from 5 COVID-19 patients and controls.
Key Insights and Ideas
- Tryptophan Metabolism is Reprogrammed: SARS-CoV-2 infection significantly alters the balance of enzymes involved in tryptophan metabolism, leading to increased production of kynurenine and its downstream metabolites. This reprogramming appears to be organ-specific, with upregulation of biogenesis enzymes and downregulation of catabolic enzymes.
- The Kynurenine-AHR-TF Axis is Activated: The increased kynurenine levels act as ligands for the Aryl Hydrocarbon Receptor (AHR), leading to its activation. Activated AHR, in turn, upregulates Tissue Factor (TF), a key initiator of the coagulation cascade. This activation occurs in endothelial cells (ECs) of the lungs and kidneys.
- A Dual Role for IDO-1: Indoleamine 2,3-dioxygenase (IDO-1) is upregulated in response to SARS-CoV-2 infection, contributing to kynurenine production. Interestingly, IDO-1 activity in sera also correlates with TF activity, suggesting a role beyond just kynurenine production.
- Translational Relevance: The findings in mice were validated in human COVID-19 patients, showing elevated kynurenine and its metabolites in their sera, along with evidence of AHR-TF axis activation.
- Therapeutic Potential: Inhibiting either AHR or IDO-1, or both, significantly suppressed TF activity, highlighting the Kynurenine-AHR-TF axis as a potential therapeutic target for preventing COVID-19-associated thrombosis.
Key Results
- In Mice: SARS-CoV-2 infection led to increased TDO2 expression in the liver and IDO-1 expression in the kidneys and lungs. Conversely, KMO and KYNU expression were downregulated in kidneys and lungs. Serum kynurenine levels were significantly increased at 4dpi. AHR and TF expression were upregulated in kidney and lung vasculature.
- In Humans: COVID-19 patients' sera showed significantly higher levels of kynurenine, kynurenic acid, anthranilic acid, and quinolinic acid compared to controls. Human kidney autopsies from COVID-19 patients revealed increased AHR and TF expression in ECs.
- In Cell Assays: Sera from COVID-19 patients induced significantly higher AHR and TF activity in endothelial cells. AHR inhibition reduced TF activity, while combined AHR and IDO-1 inhibition led to a substantial reduction in TF activity.
Limitations and Future Work
- Pharmacological Manipulation: The study used pharmacological manipulation, which can affect multiple cell types. The authors suggest that conditional knockout mice would be beneficial to establish cell-type-specific contributions.
- Organ Specificity: The study focused on two organs (kidneys and lungs) for kynurenine degradation enzymes. Further investigation into other organs is needed for a comprehensive understanding.
- Mutant Strains: SARS-CoV-2 has undergone mutations. Future studies should compare tryptophan metabolism alterations with different SARS-CoV-2 variants, as thrombotic risk persists with mutant strains.
- Combinatorial Therapies: The findings suggest that a combination of therapies targeting AHR and IDO-1 might be more effective, and this warrants further investigation. The authors also propose exploring these metabolites as potential biomarkers for guiding therapy.
Summary updated